CoChat
Sign Up
Cited by 20Lipoproteins and Cardiovascular HealthCoronary Interventions and DiagnosticsAtherosclerosis and Cardiovascular Diseases

The effect of statin therapy on plaque regression following acute coronary syndrome: a meta-analysis of prospective trials

Tang, Xuejiao, Yang, Yuan, Luo, Suxin, Zhao, Yue, Lu, Chunyan, Luo, Yongbai, Zhang, Fan, Xiao, Hua·2016·Coronary Artery Disease
DOI 10.1097/mca.0000000000000403
Open this paper in CoChat — free account

Abstract

OBJECTIVE: To investigate the effect of statins on plaque regression after acute coronary syndrome (ACS). METHODS: We carried out a meta-analysis to assess the change in plaque and plaque components in patients with ACS under statin therapy. This meta-analysis combined data of 1623 participants from eight randomized-controlled trials and seven observational studies. RESULTS: The benefits of high-intensity statin therapy on plaque regression occurred after 6 months [standardized mean difference (SMD): -0.27; 95% confidence interval (CI): -0.43 to -0.12; P=0.0006] and were sustained over 12 months (SMD: -0.14; 95% CI: -0.25 to -0.03; P=0.01). No significant decrease was observed in the plaque volume and percent plaque volume under low-dose statin treatment. After 6 months of intensive statin treatment, the plaque volume reduced significantly in patients whose follow-up LDL cholesterol levels did (SMD: -0.16; 95% CI: -0.29 to -0.03; P=0.02) or did not (SMD: -0.21; 95% CI: -0.32 to -0.09; P=0.0007) decrease to 70 mg/dl or less. There was no significant change in plaque composition volumes, but an increase was found in the percent dense calcium volume of 1.31% (95% CI: 0.55-2.07%; P=0.0007). CONCLUSION: Intensive statin therapy duration over 6 months may be as important as achieved LDL-C of less than or equal to 70 mg/dl in plaque regression following ACS. Intensive statin treatment may lead to an earlier regression compared with low-dose statin therapy.

Integrity signals

Registry

Crossref · 10.1097/mca.0000000000000403

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • This resolution concept is likely relevant to humans because large reductions in plasma LDL-cholesterol cause regression of even advanced atherosclerotic lesions, and plaque regression is accompanied by fewer atherosclerotic cardiovascular disease events.

    “This concept is likely to be relevant to humans because dramatic reductions in plasma LDL-cholesterol levels lead to the regression of even advanced atherosclerotic lesions, and plaque regression is accompanied by lower rates of atherosclerotic cardiovascular disease events210,211.”

    From Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities (2019) · cites this paper as [210]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Tang, X., Yang, Y., Luo, S., Zhao, Y., Lu, C., Luo, Y., Zhang, F., & Xiao, H.
Affiliations
Sichuan University (CN)
Corresponding author
Xiao, Hua
ORCID
Venue
Coronary Artery Disease
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2016-12
Volume
27
Issue
8
Pages
636-649
ISSN
0954-6928 (ISSN-L)
DOI
10.1097/mca.0000000000000403
OpenAlex
W2464050807
Cited by
20
References
38
Citations by year
2024: 2 · 2023: 3 · 2021: 4 · 2020: 2 · 2019: 3 · 2018: 5
FWCI
0.53
Type
journal article
Language
en
Open access
closed
Locations
  • Coronary Artery Disease (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Surgery › Coronary Interventions and Diagnostics
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
Keywords
statins, plaque regression, acute coronary syndrome, high-intensity statin therapy, low-dose statin therapy, LDL cholesterol, plaque composition, dense calcium, coronary artery disease, treatment duration
MeSH terms
Aged, Coronary Artery Disease, Coronary Vessels, Dose-Response Relationship, Drug, Female, Humans, Cholesterol, LDL, Male, Middle Aged, Prospective Studies, Risk Factors, Time Factors, Biomarkers, Chi-Square Distribution, Randomized Controlled Trials as Topic, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Acute Coronary Syndrome, Plaque, Atherosclerotic, Observational Studies as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review